Activation of the N-myc2 oncogene by integration of woodchuck hepatitis virus (WHV) DNA is a central event in woodchuck liver oncogenesis. In this study, we have evaluated the in¯uence of several cellular and viral trans-acting factors and mediators of in¯ammation on Nmyc2 promoter activity in hepatoma cell lines. Ets oncoproteins, including Ets1, Ets2 and PEA3 eciently activated a chimeric N-myc2 promoter/luciferase reporter gene. By electrophoretic mobility shift assays, we show that Ets1 and Ets2 proteins can eciently bind two consensus Ets sites located within a 59 bp sequence upstream of the N-myc2 transcription start site. Sitedirected mutagenesis of these Ets-binding motifs abolished transactivation of the N-myc2 promoter by Ets proteins. Addition of interleukin-6 (IL-6) induced a weak but reproducible activation of the N-myc2 promoter, while IL-1 was ineective. We further show that the Nmyc2 promoter can be transactivated by the hepadnavirus X protein, and that distal promoter sequences are required for both IL-6 and X responsiveness. Similar eects of these factors were observed in the context of the N-myc2 promoter activated by WHV cis-regulatory elements. In view of the high-level expression of the Nmyc2 oncogene in most woodchuck liver tumors, the Ets oncoproteins, in¯ammation-associated cytokine IL-6 and the viral X transactivator might play important roles in hepadnavirus-associated tumorigenesis.
The myc genes family contains three well-characterized proto-oncogenes c-myc, N-myc and L-myc, which share a common three exon structure and encode structurally and functionally related proteins (reviewed in DePinho et al., 1991) . These genes play important roles in the regulation of cellular proliferation, dierentiation and apoptosis. Oncogenic activation of myc genes by chromosomal translocation, gene ampli®cation, or retroviral insertion is widespread in human and animal cancers (Marcu et al., 1992) .
We recently described the presence of an additional gene of the myc family, termed N-myc2, in a subset of rodent species including woodchucks and squirrels (Fourel et al., 1990; Transy et al., 1992) . The intronless N-myc2 gene is a functional retrotransposon of the N-myc gene. Like other myc oncogenes, N-myc2 cooperates with activated H-ras in the transformation of rat embryo ®broblasts (Fourel et al., 1990) , and its targeted expression in liver cells induces hepatocellular carcinoma in transgenic mice (CA Renard and G Fourel, unpublished results) . In addition, forced expression of N-myc2 in rodent hepatic cells triggers a strong proliferative response and an increased propensity to undergo apoptosis, which is inhibited by insulin-like growth factor II (Dandri et al., 1996; Ueda and Ganem, 1996) . While N-myc2 transcripts are undetectable in normal adult hepatocytes, they are abundantly produced in a majority of liver tumors induced by woodchuck hepatitis virus (WHV) (Fourel et al., 1990) . A prominent role of WHV DNA integration in the process of N-myc2 activation has been demonstrated. In most woodchuck tumors, viral integration sites were found to be clustered either in the vicinity of the N-myc2 coding region or at a 160 ± 200 kb distance in the win locus (Fourel et al., 1990 . N-myc2 promoter activity was highly enhanced in all cases, and the capacity of WHV enhancer elements to cis-activate the N-myc2 promoter was demonstrated in transient transfection assays in hepatoma-derived cells (Fourel et al., 1996; Ueda et al., 1996a,b; Wei et al., 1992) . At preneoplastic stages, N-myc2 expression is activated in precancerous lesions similar to altered hepatic foci occurring in rats exposed to carcinogenic regimens (Toshkov et al., 1990; Yang et al., 1993; reviewed in Fourel, 1994) . At this stage however, it was not established whether N-myc2 transcription was activated through viral insertional mutagenesis or through independent, trans-acting pathways.
In a previous report, a short N-myc2 promoter including a variant TATA box and potential binding sites for several transcription factors was mapped within sequences homologous to the 5' untranslated region of the second N-myc exon . In this study, we set out to investigate cellular and viral transcriptional trans-acting factors controlling the activity of the woodchuck N-myc2 promoter in hepatoma cells.
Binding of Ets-1 and Ets-2 proteins at two dierent sites in the minimal N-myc2 promoter assays (EMSA) were performed using whole cellular extracts from insect cells infected with Ac-NPV-Ets1 or Ac-NPV-Ets2 recombinant baculoviruses as described (Bosselut et al., 1990) . Synthetic oligonucleotides used in this study were as follows: and Thummel, 1990) . The capacity of each of the two consensus Etsbinding motifs from N-myc2 promoter to compete for binding of Ets1 to the high-anity Ets-binding site E74 was ®rst investigated. Incubation of the 32 P-labeled E74 probe with the Ets1-containing extracts yielded a major DNA-protein complex (Figure 2 , lanes 2 and 8) that did not appear using extracts from insect cells infected with the empty vector (not shown). In competition experiments, in which a 100-to 400-fold excess of the unlabeled N-myc2.Pu1 or N-myc2.Pu2 oligonucleotides was included with the labeled E74 probe, both N-myc2 oligos competed eectively for the DNA-protein complex (lanes 3, 4, 9 and 10); the mutated oligos were ineective (lanes 5, 6, 11 and 12) . Similarly, when E74 was used as a probe, unlabeled N-myc2.Pu2 (Figure 2 , lanes 21 and 22) as well as N-myc2.Pu1 oligonucleotides (data not shown) competed eectively for Ets2 protein binding, while a mutated oligo (lanes 23 and 24) had no eect. Direct assays were conducted to determine whether the N-myc2.Pu1 and N-myc2.Pu2 oligonucleotides could also form speci®c complexes with cell extracts containing the Ets1 protein. As shown in Figure 2 , lane 14, the N-myc2.Pu1/Ets1 interaction was detected as a major band with expected mobility in gel retardation assay. The unlabeled wild type N-myc2.Pu1 (lanes 15 and 16), N-myc2.Pu2 and E74 oligonucleotides (not shown) competed for Ets1 protein binding, while the mutated oligo (lanes 17 and 18) was ineective. The abilities of N-myc2.Pu1 and Nmyc2.Pu2 to bind Ets2 protein were similarly demonstrated in gel retardation assays (results not shown).
The N-myc2 promoter is eciently activated by Ets expression
Chimeric N-myc2/luciferase constructs were generated by inserting dierent fragments of the N-myc2 promoter in pSVOALD5', a plasmid carrying the promoterless luciferase (LUC) gene and SV40 small-t intron/polyadenylation signal (De Wet et al., 1987) . The full length (71100) N-myc2 promoter consists of a 1174 bp HindIII ± BglII fragment, and the 7332 construct contains a 406 bp RsaI ± BglII DNA fragment as shown in Figure 1 . The 759 and 737 constructs were obtained after PCR ampli®cation of 133 bp and 111 bp N-myc2 sequences spanning the transcription initiation site. The DNA sequence of the fragments generated by PCR was con®rmed by nucleotide sequencing. In all constructs, N-myc2 sequences terminated at the BglII site (position +74) and included the ®rst 27 bp of the N-myc2 open reading frame (ORF) fused in frame with the LUC ORF.
Hepatoma-derived Huh7 cells were transfected with expression plasmids directing the expression of either Ets1, Ets2 or PEA3 together with reporter constructs carrying the LUC gene under control of the N-myc2 promoter. The pEts1 and pEts2 plasmids carrying Ets1 and Ets2 cDNAs linked to the SV40 early promoter have been described previously (Prosser et al., 1992) , and the plasmid carrying a PEA3 cDNA controlled by the SV40 early promoter was a gift from J Hassell. Cells were transfected by the calcium phosphate coprecipitation method, using 15 mg of plasmid DNA per 25 cm 2 dishes and 2 mg of the b-galactosidase expression vector pCH110 as an internal control for transfection eciency. Luciferase activity was determined from cell lysates prepared 24 h or 48 h after (Poli and Ciliberto, 1994) , which is responsible for IL-6-responsiveness of a subset of IL-6-sensitive promoters, and putative Ets-binding sites (Ets-Pu1 and Ets-Pu2) are boxed. CAAT, Sp1, TATA and initiator (Inr) motifs are overlined. The boundaries of the N-myc2 domains homologous to N-myc exons 1 and 2 are indicated transfection as described previously (Wei et al., 1992) . Overexpression of Ets1 or ETs2 resulted in strong activation of the full length N-myc2 promoter ( Figure  3 , lanes 2 and 3), and the minimal (759) N-myc2 promoter was similarly activated (Figure 3 , lines 5, 6 and 7). In contrast, transactivation was appreciably impaired by deletion of sequences 759 nt to 737 nt that contain the 5' most purine box (Pu1) (lanes 10 and 11). Mutations were introduced into the N-myc2Pu1 site (ACCAAG) and Pu2 site (CCCAAA) by using the enzymatic inverse PCR method (Stemmer and Morris, 1992) . The response elicited by the Ets expression vectors was signi®cantly decreased by mutating the Pu1 motif and, to a lesser extent, the Pu2 motif ( Figure 3 , lines 14 ± 15 and 18 ± 19), and combination of Pu1 and Pu2 mutations essentially abrogated activation of the minimal N-myc2 promoter by Ets-proteins (lanes 22 ± 23). In parallel studies, the Herpes simplex virus thymidine kinase (TK) promoter used as a negative control was found totally unresponsive ( Figure 3 , lanes 25 ± 28). Correct transcription initiation at the normal Nmyc2 mRNA start site was con®rmed by RNase protection assays (data not shown). In cotransfections with the PEA3 expression plasmid, activation of the Nmyc2 promoter was also observed, although the levels were generally twofold lower than with Ets1 or Ets2 (Figure 3, lanes 4, 8, 12, 16 and 20) . In contrast, pD318 ± 363, which carries a Ets1 mutant harboring a deletion in the DNA-binding domain (Boulukos et al., 1989) had no trans-acting activity (data not shown). Finally, transactivation could also be observed at similar levels in HepG2 cells but not in CCL13 cells, an epithelial-like cell line derived from human liver, suggesting the involvement of unidenti®ed, cell-speci®c cofactor(s). These data taken together demonstrate that Ets oncoproteins bind two dierent motifs within the minimal N-myc2 promoter and eciently activate transcription driven by this promoter in dierentiated hepatoma cell lines. Residual Ets-transactivation upon mutation of both of these sites may be due to the existence of unidenti®ed, degenerated sequences in the same region; alternatively, it may involve Ets proteins only as indirect eectors. Ets family members are known to require cooperation with other factors for their activity (Schneikert et al., 1992; Wasylyk et al., 1993) . Notably, as in several cellular and viral promoter/enhancer regions, N-myc2 promoter sequences harbor a canonical Sp1 binding site located upstream of the 5' Purine box (see Figure 1) . Additional studies will be required to determine whether synergistic interactions between Ets and Sp1 contribute in N-myc2 promoter activation. On the other hand, an hepatocytelike cellular environment appeared to be necessary for Nmyc2 responsiveness to Ets proteins, which may convey the requirement for a liver-speci®c co-factor.
Interleukin IL-6 can increase N-myc2 promoter activity WHV infection induces a chronic in¯ammatory process in the liver of long term carrier woodchucks (Popper et al., 1987) , and altered hepatic foci that overexpress the N-myc2 gene were frequently detected in the vicinity of portal tract in¯ammatory cell lesions, which are capable of producing a variety of cytokines (Yang et al., 1993) . Interleukin-6 (IL-6) is a multifunctional cytokine, which causes cell growth and dierentiation and induces the synthesis of acute phase proteins in hepatocytes (Heinrich et al., 1990) . Two families of transcription factors mediate IL-6 eects on hepatic gene transcription. While C/EBP and NF-kB transcription factors are involved in activation of class I acute- Figure 2 Analysis of Ets1 and Ets2 binding to two consensus purine boxes in the minimal N-myc2 promoter. Electrophoretic mobility shift assays were performed using extracts (10 mg) from insect cells infected with either Ac-NPV-Ets1 or Ac-NPV-Ets2 recombinant baculoviruses, and oligonucleotides E74 or N-myc2.Pu1 as 32 P-labeled probes (100 fmol/assay) as indicated on the top. Assays contained either no competitor (lanes 2, 8, 14 and 20) or a 100-to 400-fold molar excess of the unlabeled oligonucleotides Nmyc2.Pu1 or N-myc2.Pu2, as indicated above each lane. Wild type (wt) and mutated (mut) oligonucleotide sequences are described in the text. As controls, the labeled probes were analysed in the absence of lysate (lanes 1, 7, 13 and 19) or with lysates from insect cells infected with an empty baculovirus vector (Bosselut et al., 1990 ) (data not shown). The bound complexes were resolved in 5% polyacrylamide gels and visualized using a PhosphorImager (Molecular Dynamics) phase protein genes, for which maximal expression is reached by a combination of IL-1 and IL-6, the acutephase response factor APRF/ IL6-REBP/ Stat3 mediates IL-6 responsiveness of class II genes, which are responsive only to IL-6 and related cytokines. Examination of N-myc2 promoter sequences (see Figure 1 ) revealed the presence of two putative IL-6 responsive elements (Poli and Ciliberto, 1994) , similar to those of type II acute-phase protein genes such as the b-®brinogen and a2 macroglobulin genes (Hocke et al., 1992) . To investigate the responsiveness of the Nmyc2 promoter to IL-6, hepatoma-derived HepG2 cells known to express the high anity membrane receptor to IL-6 (a kind gift of G Courtois) were transfected with dierent N-myc2 promoter/LUC reporter constructs, and recombinant human IL-6 (Boehringer Mannheim) was added to the culture medium 24 h after transfection at 60 U/ml. Cells were harvested 3 days later. In the presence of IL-6, the N-myc2 promoter activity was reproducibly enhanced by 2.5-fold ( Figure 4, lane 2) . This value is comparable to that obtained with pb-®b, a plasmid constructed by inserting the promoter of the IL-6-responsive human b-®brinogen gene (Dalmon et al., 1993) at the HindIII site of pSVOALD5' (lane 8). In contrast, no activation was observed upon deletion of N-myc2 promoter sequences upstream of position 7332 (lane 5). These data suggest that the two potential APRF sites located at positions 7108 to 7116 and 7281 to 7289 are either nonfunctional or not sucient on their own for IL-6 induction, and that the contribution of distal Nmyc2 promoter sequences is required for IL-6 responsiveness. However, examination of the nucleotide sequence of the full-length N-myc2 promoter (unpublished data) did not provide evidence for the presence of additional consensus IL-6-responsive elements. An alternative hypothesis is that the APRF sites might be involved in combination with the upstream sequences, as described for IL-6-mediated induction of the junB promoter (Nakajima et al., 1993) . In the same experimental conditions, the in¯ammation cytokine IL-1 had no eect on the activity of the N-myc2 and b-®brinogen promoters (Figure 4 , lanes 3, 6 and 9), supporting the notion that N-myc2, like the b-®brinogen gene, belongs to the group of hepatic genes that respond to IL-6 but not to IL-1.
The hepadnaviral X transactivator activates the N-myc2 promoter
The hepadnaviral X protein was shown to transactivate several genes implicated in cellular growth, such as cmyc, c-fos and c-jun (reviewed in Rossner, 1992 ). This Plasmids were transfected into Huh7 cells or cotransfected with a plasmid expressing Ets1, Ets2 or PEA3 protein, and LUC activity was assayed 24 h after transfection. Two independent clones of each construct were analysed, and comparisons were carried out on identical plates prepared at the same time. The bar diagram depicts the mean (+standard error of the mean) relative LUC activities obtained in three independent transfection experiments. The activity of the full-length (71100) Nmyc2 promoter construct was arbitrary set at one, and numbers indicate fold-activation led us to address whether the X protein is able to activate the N-myc2 promoter. CCL13 cells were cotransfected with pHBx2S, an expression plasmid carrying the HBV X gene under control of the SV40 early promoter/enhancer (KekuleÂ et al., 1993) and LUC reporter constructs as described above. Cotransfection of low amounts (30 to 250 ng) of pHBx2S resulted in activated transcription from both the Nmyc2 and SV40 promoters, but transactivation was less ecient using a higher amount of pHBx2S ( Figure 5 , lanes 1 ± 6 and 9 ± 14). This may be attributed either to a squelching eect, or to the recently described cytotoxic eects of HBx overexpression (Oguey et al., 1996) . Deleting N-myc2 promoter sequences upstream of nt-322 abrogated transactivation (lanes 7 and 8) indicating that sequences responsible for this activation are contributed by distal N-myc2 promoter sequences. The presence of X protein in lysates from transiently transfected cells was demonstrated by Western blotting (data not shown). Interestingly, the N-myc2 promoter proved to be unresponsive to X protein when recipient cells were serum-starved for 3 days before transfection (data not shown).
Taking into account the previously reported transactivation of c-myc by the X protein (Balsano et al., 1991) and that of the classical N-myc gene (our unpublished results), each potential target gene for WHV DNA integration in woodchuck tumors also emerges as a target of X transactivation. The mechanisms of X-induced transcriptional activation are not clear, although there is accumulating evidence for both a nuclear eect directly on the transcription machinery, and a cytoplasmic eect involving signal transduction pathways (reviewed in Yen, 1996) . In our system, the N-myc2 promoter was non-responsive to X overexpression in serum-starved cells, which suggests the involvement of serum-sensitive intracellular mediators. Because the N-myc2 promoter is eciently activated by Ets proteins, which are subject to rapid and transient phosphorylation events in response to mitogenic signals (Yang et al., 1996) , we initially envisioned that Ets proteins might be the terminal eectors of X-induced trans-activation of the N-myc2 promoter. However, the ®nding that the minimal Nmyc2 promoter is responsive to Ets proteins but not to X expression argues against this hypothesis. Conver- Figure 4 Dierential response of the N-myc2 promoter to the in¯ammatory cytokines IL-1 and IL-6. HepG2 cells were transfected with the 71100 and 7332 N-myc2/LUC constructs, in the presence or absence of IL-1 or IL-6 (60 U/ml). Cytokines were added into the medium 24 h after transfection, and cells were harvested after a 72 h incubation. The b-®b/LUC plasmid carrying sequences of the IL-6 responsive human b-®brinogen promoter was analysed in parallel. Legend is otherwise the same as in Figure 3 sely, the requirement for upstream sequences¯anking the N-myc homology region for X transactivation as well as for IL-6 responsiveness may suggest that this region contains previously unrecognized regulatory elements.
Cis-and trans-activating pathways can act in concert to trigger high level activity of the N-myc2 promoter
In more than 80% of woodchuck liver tumors, WHV DNA integration either in the N-myc2 locus or in the physically linked win locus is associated with enhanced N-myc2 promoter activity. We have previously shown that this promoter is activated in cis by WHV enhancer sequences, mainly by the We2 activator (Fourel et al., 1996; Wei et al., 1992) . We therefore investigated the eects of trans-acting factors as described above in the context of the N-myc2 promoter placed under cisregulatory in¯uence of the viral enhancer. To this aim, the 1647 bp ApaI ± BglII DNA fragment (WHVenh) encompassing the viral enhancers 1 and 2 on the WHV8 genome (Girones et al., 1989) was inserted upstream of either the full length or the minimal Nmyc2 promoter in a LUC vector. The resulting constructs were transfected in Huh7 cells. Insertion of the viral sequences upstream of the 71100 N-myc2 promoter resulted in fourfold induction of LUC activity ( Figure 6, lanes 1 and 3) . Coexpression of Ets2 led to a further 15-fold activation, resulting in a total 60-fold activation as compared to the native promoter activity (lane 4). Thus, the eects of combined cis-activation by the WHV enhancer and trans-activation by Ets were clearly multiplicative. Each of these activating pathways proved even more eective in combination with the minimal N-myc2 promoter, resulting in a ®nal 250-fold activation of transcription initiation over basal activity (lane 8). Similar results were obtained upon expression of either Ets1 or PEA3 proteins (data not shown). Mutation of both the Pu1 and Pu2 boxes reduced transactivation by Ets to approximately fourfold in the presence of juxtaposed viral sequences (Figure 6 , lanes 9 ± 10), a value similar to that obtained with the mutated N-myc2 promoter alone. These data indicate that only Ets-binding sites located in the N-myc2 promoter and not in the viral sequences mediated activation by Ets proteins.
Integrated viral sequences in woodchuck tumors may consist in subgenomic WHV fragments or in large, rearranged sequences made of concatemerized fragments. We recently cloned a 2.85 kb long, highly rearranged viral sequence inserted into the win locus in a woodchuck liver tumor. This sequence (WHVint) contains one copy of the enhancer 1 and ®ve copies of the enhancer 2 (Flajolet et al., 1997) . Introduction of WHVint upstream of the minimal N-myc2 promoter resulted in a 45-fold induction of LUC activity ( Figure  6 , compare lanes 5 and 11). The enhancer activity of the complex integrant sequences was therefore eight times higher than that of the linear WHVenh fragment (compare lanes 7 and 11). N-myc2 promoter under the marked in¯uence of this sequence remained highly responsive to Ets2, reaching a remarkably high (450-fold) level of induction (lane 12). These data strongly suggest that trans-activation by Ets proteins and cisactivation by integrated viral sequences can act in concert to activate N-myc2 promoter to very high levels in woodchuck liver tumors.
The growing family of Ets transcription factors has been implicated in the regulation of gene expression in a variety of biological processes, including growth control, transformation, T-cell activation, and developmental programs in many organisms (reviewed in Wasylyk et al., 1993) . Although individual members are dierentially expressed, they show similar binding Figure 6 Cooperative eects of cis-and trans-activating pathways on N-myc2 promoter activity. Left part: WHV fragments inserted 5' of the 71100 or 759 N-myc2 promoter in LUC constructs are shown as boxes. WHVenh is a linear ApaI-BglII fragment of the WHV8 genome (position 887 ± 2534) (Girones et al., 1989) ; WHVint represents a highly rearranged, 2.85 kb long viral sequence integrated into the win locus in a woodchuck liver tumor. The WHV enhancers 1 and 2 are shown as stripped and black boxes. N-myc2 promoter doubly mutated at the Pu1 and Pu2 motifs is shown as a black box. The constructs were cotransfected with a Ets2 expression vector in Huh7 cells. Results are presented as the ratio of LUC activity for each construct versus the 71100 N-myc2 promoter construct and are means (+s.e.m.) of at least three independent transfections. Numbers refer to the fold-activation of LUC activity in the presence of co-expressed Ets2 protein speci®cities and the identi®cation of the Ets-family members implicated in N-myc2 activation in woodchuck liver is a dicult task. Ets2 expression has been shown to increase during liver regeneration (Bhat et al., 1987) , and we observed that both Ets1 and Ets2 mRNAs are produced at signi®cant levels in tumorous and nontumorous liver tissues from WHV-infected woodchucks (our unpublished data). In this study, both Ets-1 and Ets-2 proteins were found to bind the two purine boxes in the N-myc2 promoter, and overexpression of Ets1, Ets2 or PEA3 was almost equally eective in activating the N-myc2 promoter, the fold-induction being high compared with other documented systems (Bosselut et al., 1990; Xin et al., 1992) . A variety of intracellular pathways elicited in virus-infected liver and in hepatomas may lead to the modulation of Ets-proteins activity, which may in turn contribute to N-myc2 activation. This hypothesis is supported by the recent ®nding that the activity of Ets2 is regulated by the Ras-Raf-MEK-MAP kinase cascade (McCarthy et al., 1997) .
The eect of IL-6 on the activity of the N-myc2 promoter linked to the viral fragment WHVenh was investigated in HepG2 cells. In these cells, we observed an eightfold activation of the N-myc2 promoter by the cis-acting eect of the WHV enhancer. Exposure of HepG2 cells to IL-6 resulted in further twofold activation of LUC expression (data not shown). Collectively, the data presented here show that IL-6 induces a moderate increase of the activity of the N-myc2 promoter, both in native con®guration and when linked to the WHV enhancer. Thus, in woodchuck liver, IL-6 might contribute in activating N-myc2 expression both at preneoplastic and tumorous stages. It should not be inferred from the mild eect observed in our experimental conditions that IL-6 could play only a minor role in N-myc2 activation, as the eects might be much more pronounced in vivo in the context of in¯amed liver.
During the multistep process of WHV-associated liver carcinogenesis, the woodchuck N-myc2 gene is frequently activated in altered hepatic foci, suggesting that the N-myc2 oncoprotein may confer a selective advantage for malignant conversion at early stages of the carcinogenic process (Yang et al., 1993) . It is tempting to speculate that in chronic viral infections, N-myc2 expression might be activated in trans by intracellular signal transduction pathways triggered by liver in¯ammation or by the expression of viral proteins such as the X transactivator. Then at tumorous stages, overexpression of N-myc2 in a majority of woodchuck hepatocellular carcinomas is systematically associated with WHV DNA integration into the N-myc2 or win loci. Thus, cis-activation by integrated viral enhancer elements and trans-activation by cellular and viral factors may act in concert to drive high level expression of the N-myc2 oncogene.
However, recent evidence points to the N-myc2 gene being constitutively repressed within chromatin in normal woodchuck cells, although N-myc2 sequences are not methylated (our unpublished results). In woodchuck hepatomas, integration of WHV DNA in the N-myc2 and win loci could thus play a dual role, as recently described for other enhancers (Walters et al., 1996) . It would ®rst alleviate a negative control imposed on the promoter and confer accessibility to the transcription machinery, and secondly, it would directly activate transcription initiation. An array of trans-acting partners could then come into play sequentially, to eventually potentiate the oncogenic activation of N-myc2. As a consequence, the transactivation pathways described in this study would not lead to N-myc2 activation unless derepression occurs. Further analysis of the hepatic foci that develop in chronic WHV infections might allow to determine whether integration of viral DNA in the N-myc2 or win loci is responsible for upregulation of N-myc2 at this early step of the transformation process. Another recently identi®ed factor in the progression of woodchuck liver tumors is the inhibition of N-myc2-induced hepatocyte apoptosis by the insulin-like growth factor II (IGF-II) (Dandri et al., 1996; Ueda and Ganem, 1996) . Indeed, altered hepatic foci in chronically infected livers usually express both N-myc2 and IGF-II, but N-myc2 expression is still low as compared to malignant tumors. This suggests that Nmyc2 superactivation triggers secondary steps that will eventually lead to malignant transformation. These events, that may include alleviation of lymphokine/ growth factor dependency, remain to be elucidated.
